BiomX Inc. (PHGE)
Largest Insider Buys in Sector
PHGE Stock Price History Chart
PHGE Stock Performance
About BiomX Inc.
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a …
Insider Activity of BiomX Inc.
Over the last 12 months, insiders at BiomX Inc. have bought $0 and sold $13,351 worth of BiomX Inc. stock.
On average, over the past 5 years, insiders at BiomX Inc. have bought $137,723 and sold $165,720 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,327 shares for transaction amount of $0 was made by OrbiMed Israel BioFund GP Limited Partnership (10 percent owner) on 2024‑03‑15.
List of Insider Buy and Sell Transactions, BiomX Inc.
| 2024-05-15 | Sale | 10 percent owner | 24,344 0.0486% | $0.38 | $9,280 | -45.38% | ||
| 2024-03-15 | 10 percent owner | 4,327 – | $0 | $0 | -10.52% | |||
| 2023-11-29 | Sale | Chief Business Officer | 10,914 0.0292% | $0.37 | $4,072 | -7.33% | ||
| 2023-05-22 | Chief Business Officer | 3,192 0.01% | $0.27 | $872 | +28.68% | |||
| 2023-05-19 | Chief Business Officer | 6,521 0.0204% | $0.28 | $1,832 | +25.00% | |||
| 2023-05-18 | Chief Business Officer | 1,201 0.0037% | $0.27 | $328 | +26.35% | |||
| 2023-02-27 | 10 percent owner | 348,000 0.7935% | $0.24 | $85,260 | -12.50% | |||
| 2022-11-04 | Sale | director | 1,501 0.005% | $0.38 | $567 | -12.50% | ||
| 2022-11-03 | Sale | director | 2,000 0.0065% | $0.37 | $732 | -12.37% | ||
| 2022-11-02 | Sale | director | 2,416 0.0081% | $0.36 | $867 | -7.76% | ||
| 2022-11-01 | Sale | director | 1,300 0.0043% | $0.36 | $473 | -10.00% | ||
| 2022-10-31 | Sale | director | 3,300 0.0114% | $0.37 | $1,224 | -6.94% | ||
| 2022-10-28 | Sale | director | 1,526 0.0048% | $0.36 | $543 | -10.88% | ||
| 2022-10-27 | Sale | director | 1,505 0.0051% | $0.36 | $548 | -5.87% | ||
| 2022-10-26 | Sale | director | 12,500 0.0386% | $0.35 | $4,325 | -10.13% | ||
| 2022-10-25 | Sale | director | 3,072 0.0102% | $0.36 | $1,121 | -7.86% | ||
| 2022-10-24 | Sale | director | 5,900 0.0191% | $0.35 | $2,059 | -5.82% | ||
| 2022-10-21 | Sale | director | 5,400 0.0177% | $0.37 | $1,998 | -9.81% | ||
| 2022-10-20 | Sale | director | 6,636 0.0219% | $0.37 | $2,482 | -10.53% | ||
| 2022-10-19 | Sale | director | 4,501 0.0142% | $0.37 | $1,652 | -12.37% |
Insider Historical Profitability
| OrbiMed Israel BioFund GP Limited Partnership | 10 percent owner | 13773653 76.9658% | $0.72 | 9 | 1 | <0.0001% |
| Oron Assaf | Chief Business Officer | 0 0% | $0.72 | 3 | 1 | +26.68% |
| Chimovits Erez | director, 10 percent owner | 2313489 12.9276% | $0.72 | 7 | 0 | <0.0001% |
| GROSSMAN JONAS | director | 372717 2.0827% | $0.72 | 4 | 0 | <0.0001% |
| Amusa Gbolahan | director | 262871 1.4689% | $0.72 | 1 | 0 |
Institutional Investor Ownership
| Ikarian Capital LLC | $4.87M | 15.5 | 10.82M | New | +$4.87M | 0.67 | |
| Deerfield Management | $2.75M | 8.75 | 6.11M | New | +$2.75M | 0.01 | |
| OrbiMed | $2.03M | 6.47 | 4.52M | 0% | +$0 | 0.02 | |
| Johnson & Johnson | $865,440.00 | 2.76 | 1.92M | -9.85% | -$94,590.40 | 0.02 | |
| Renaissance Technologies | $36,000.00 | 0.12 | 80,600 | -26.92% | -$13,262.83 | <0.0001 |